Based on the above findings, this study raises an alternative strategy for targeting NG2 to effectively treat BRAF-mutant thyroid cancer cells by combining Sorafenib or Lenvatinib and BRAF inhibitor. This evidence concerns the gene CSPG4 and thyroid gland carcinoma.